One Standard, Many Markets: What FDA, EMA, and PMDA Actually Agree OnReal-World EvidenceRegulatoryLife sciencesReal-World Data
A conversation with Dr. Ronac Mamtani on the evidence that moves oncology forwardPoint of careHealth SystemsAcademicsReal-World Data
ASCO 2026: Translating oncology innovation into real-world impactReal-World EvidenceLife sciencesReal-World Data
Rewriting the real-world evidence playbook for clinical developmentReal-World EvidenceTrial designArtificial intelligenceData QualityLife sciencesReal-World DataClinical development
ISPOR 2026 reflections: AI, access, and the evolving role of RWE in oncologyReal-World EvidenceRegulatoryHTA and Market AccessArtificial intelligenceLife sciencesHEOR / RWEReal-World Data
From innovation to strategic insight: making sense of rapid advances in bladder cancer careReal-World EvidenceLife sciencesReal-World DataBladder cancer
Unlocking the next level of RWD: Flatiron’s Scientific VisionReal-World EvidenceArtificial intelligenceLife sciencesReal-World Data
The real-world perspective: Why global RWE matters in modern oncologyReal-World EvidenceProstate CancerArtificial intelligenceLife sciencesReal-World Data
High-quality, validated AI-enabled research: Insights from recent prostate cancer researchValue-based careReal-World EvidenceProstate CancerArtificial intelligenceData QualityLife sciencesReal-World Data